Glossary of patent law terms

Sisvel Announces the Launch of the 5G Multimode (5G MM) Licensing Program

Retrieved on: 
Wednesday, December 14, 2022

Sisvel International S.A. (Sisvel) today announced the launch of its 5G Multimode (5G MM) Licensing Program.

Key Points: 
  • Sisvel International S.A. (Sisvel) today announced the launch of its 5G Multimode (5G MM) Licensing Program.
  • The 5G MM Program offers a single solution to license Standard Essential Patents (SEPs) for the use of cellular standards up to and including 5G.
  • Having a single patent pool will help eliminate confusion in the market and increase cellular licensing efficiencies for implementers and licensors alike, comments Donald Chan, the program manager of the Sisvel 5G MM Licensing Program.
  • Further information about the terms and conditions of the 5G MM licensing offer is available on Sisvels website: https://www.sisvel.com/licensing-programs/wireless-communications/5g-mul... .

LexisNexis expands its Intellectual Property Solutions suite with the acquisition of IPlytics

Retrieved on: 
Wednesday, November 9, 2022

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- LexisNexis® Legal & Professional, part of RELX, today announced that it has acquired IPlytics, a leading IP intelligence company that enables the analysis of technology landscapes and competition for industries where standards and patents matter by providing access to multiple databases connecting patents, Standard Essential Patents (SEPs), standards, and technical standards contributions. The acquisition extends the vision of LexisNexis Intellectual Property Solutions to bring clarity to innovation and help companies worldwide to be more effective at bringing meaningful innovations into the world.

Key Points: 
  • The acquisition extends the vision of LexisNexis Intellectual Property Solutions to bring clarity to innovation and help companies worldwide to be more effective at bringing meaningful innovations into the world.
  • "We are delighted to welcome the IPlytics team to LexisNexis," said LexisNexis Intellectual Property Solutions President Andrew Matuch.
  • After the acquisition, IPlytics platform will become part of the LexisNexis Intellectual Property workflow and analytics solutions portfolio.
  • "It is with great enthusiasm that we join forces with LexisNexis Intellectual Property Solutions," said Tim Pohlmann, Founder and CEO of IPlytics.

LexisNexis expands its Intellectual Property Solutions suite with the acquisition of IPlytics

Retrieved on: 
Wednesday, November 9, 2022

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- LexisNexis® Legal & Professional, part of RELX, today announced that it has acquired IPlytics, a leading IP intelligence company that enables the analysis of technology landscapes and competition for industries where standards and patents matter by providing access to multiple databases connecting patents, Standard Essential Patents (SEPs), standards, and technical standards contributions. The acquisition extends the vision of LexisNexis Intellectual Property Solutions to bring clarity to innovation and help companies worldwide to be more effective at bringing meaningful innovations into the world.

Key Points: 
  • The acquisition extends the vision of LexisNexis Intellectual Property Solutions to bring clarity to innovation and help companies worldwide to be more effective at bringing meaningful innovations into the world.
  • "We are delighted to welcome the IPlytics team to LexisNexis," said LexisNexis Intellectual Property Solutions President Andrew Matuch.
  • After the acquisition, IPlytics platform will become part of the LexisNexis Intellectual Property workflow and analytics solutions portfolio.
  • "It is with great enthusiasm that we join forces with LexisNexis Intellectual Property Solutions," said Tim Pohlmann, Founder and CEO of IPlytics.

Omni Bridgeway bolsters intellectual property capabilities with specialist Michael Munsch

Retrieved on: 
Monday, October 17, 2022

COLOGNE, Germany, Oct. 17, 2022 /PRNewswire/ -- Omni Bridgeway is pleased to announce that Mr. Michael Munsch has joined the company's international intellectual property team as an Investment Manager and Senior Legal Counsel.

Key Points: 
  • COLOGNE, Germany, Oct. 17, 2022 /PRNewswire/ -- Omni Bridgeway is pleased to announce that Mr. Michael Munsch has joined the company's international intellectual property team as an Investment Manager and Senior Legal Counsel.
  • Based in Cologne, Michael is responsible for originating, assessing, and managing funded cases in EMEA with an emphasis on intellectual property litigation.
  • Prior to Omni Bridgeway, Michael was a Counsel at renowned German law firm Meissner Bolte, where he advised clients primarily on patent litigation.
  • Michael Munsch commented, "I am thrilled to be joining Omni Bridgeway which I consider the most skilled and respected legal finance provider in the industry.

Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER™  Platform’s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference

Retrieved on: 
Thursday, September 29, 2022

By targeting virus membranes and remaining well-tolerated in vivo, CLAROMERS may be able to retain these characteristics against current and future variants of concern.

Key Points: 
  • By targeting virus membranes and remaining well-tolerated in vivo, CLAROMERS may be able to retain these characteristics against current and future variants of concern.
  • Data was presented by Maxwell Biosciences Chief Scientific Officer and Co-Inventor, Kent Kirshenbaum, PhD, on Thursday, September 29, 2022, at the Options for Control of Influenza (OPTIONS XI) conference.
  • Data was presented under the abstract title, CLAROMERS: Synthetic Oligomer Mimics of Antimicrobial Peptides for Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses.
  • To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com , or follow us on Twitter and LinkedIn .

Maxwell Biosciences to Present Data on CLAROMERTM Platform’s Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference

Retrieved on: 
Thursday, September 22, 2022

Kent Kirshenbaum, PhD, Maxwell Biosciences Chief Scientific Officer and Co-Inventor, will present the abstract, CLAROMERS: Synthetic Oligomer Mimics of Antimicrobial Peptides for Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses, on Thursday, September 29, 2022, at 2:06 BST.

Key Points: 
  • Kent Kirshenbaum, PhD, Maxwell Biosciences Chief Scientific Officer and Co-Inventor, will present the abstract, CLAROMERS: Synthetic Oligomer Mimics of Antimicrobial Peptides for Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses, on Thursday, September 29, 2022, at 2:06 BST.
  • What makes Maxwells CLAROMER platform unique from standard antivirals is its ability to combat a broad spectrum of viruses, bacteria and fungi, said Maxwell Biosciences CEO and Co-Founder Joshua McClure.
  • We look forward to presenting results from our most recent research on ways to potentially innovate the treatment of COVID-19 and other infectious pathogens."
  • Founded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics synthetic compounds that mimic and improve upon biomolecules.

GLOBAL INNOVATOR IN DRY EYE TREATMENT, THERMAMEDX TO SEEK INVALIDATION OF OCUGIENE PATENT CLAIMS

Retrieved on: 
Wednesday, August 10, 2022

GLOBAL INNOVATOR IN DRY EYE TREATMENT, THERMAMEDX TO SEEK INVALIDATION OF OCUGIENE PATENT CLAIMS

Key Points: 
  • GLOBAL INNOVATOR IN DRY EYE TREATMENT, THERMAMEDX TO SEEK INVALIDATION OF OCUGIENE PATENT CLAIMS
    EverTears eye pads were developed in collaboration with ThermaMEDx co-founder and world-renowned ocular professor and optometrist, Dr. Michel Guillon.
  • Professor Guillon's research and clinical work to create new treatments for ocular surface issues like dry eye disease spans nearly 40 years.
  • ThermaMEDx is preparing petitions for inter partes review (IPR) directed to Ocugiene patents, including U.S. Patent Nos.
  • ThermaMEDx's IPR petitions will be filed with the USPTO's Patent Trial and Appeal Board and will request invalidation of certain claims in these patents.

Black Swan Graphene Provides Corporate Update

Retrieved on: 
Wednesday, August 10, 2022

TORONTO, Aug. 10, 2022 /PRNewswire/ - Black Swan Graphene Inc. ("Black Swan" or the"Company") (TSXV: SWAN) is pleased to provide a corporate update following its first day of trading on the Toronto Venture Exchange ("TSXV") on August 9, 2022.

Key Points: 
  • TORONTO, Aug. 10, 2022 /PRNewswire/ - Black Swan Graphene Inc. ("Black Swan" or the"Company") (TSXV: SWAN) is pleased to provide a corporate update following its first day of trading on the Toronto Venture Exchange ("TSXV") on August 9, 2022.
  • Mr. Edwards joins Black Swan Graphene from Thomas Swan & Co. Ltd., where he was the head of the Advanced Materials Division, where the company's graphene processing technology was originally developed;
    The appointment of Mr. Henri Wilhelm, as Black Swan Graphene's Vice-President Technology.
  • Simon Marcotte, President and Chief Executive Officer of Black Swan Graphene, stated: "We couldn't be more excited to see Black Swan Graphene progress so rapidly since its inception, in latter half of 2021.
  • Nouveau Monde and Black Swan Graphene have entered into a non-binding letter of intent, whereby Black Swan Graphene would establish its graphene processing technology in Nouveau Monde's graphite concentrate production facility, resulting in a fully integrated production supply chain from graphite ore in the ground, through graphite concentrate, and to graphene finished products.

Sisvel Launches a Patent Pool on Wi-Fi 6

Retrieved on: 
Tuesday, July 19, 2022

Sisvel International S.A. (Sisvel) today announced the launch of a patent pool on Wi-Fi 6 technology.

Key Points: 
  • Sisvel International S.A. (Sisvel) today announced the launch of a patent pool on Wi-Fi 6 technology.
  • Along with the Wi-Fi 6 pool, Sisvel also debuted a new structured payment plan the Licensing Incentive Framework for Technologies (LIFT).
  • To facilitate early adoption of licenses, Sisvel created a new royalty scheme, the Licensing Incentive Framework for Technologies (or LIFT), which will be available to licensees of this new pool.
  • The patent pool will increase transparency of patent licensing and reduce licensing disputes in the field.

Sports Data Labs, Inc. Announces Issuance of U.S. Patent Covering its Novel SaaS-Based, Real-Time Health Diagnostics and Sensor Interoperability System

Retrieved on: 
Wednesday, July 13, 2022

11,382,510 to the company covering a novel remote health monitoring and biofeedback system operable for real-time, two-way, direct communication with sensors and sensing systems via the use of a browser-based web application.

Key Points: 
  • 11,382,510 to the company covering a novel remote health monitoring and biofeedback system operable for real-time, two-way, direct communication with sensors and sensing systems via the use of a browser-based web application.
  • SD Labs issued patent, entitled Biological Data Tracking System and Method, facilitates collection, analysis, and distribution of data from any number of sensors and sensing systems including wearables into a single system for real-time health monitoring and biofeedback.
  • The issued patent will provide SD Labs with exclusivity for its invention in the U.S. until February 2039.
  • SD Labs also provides data acquisition and monetization solutions for buyers and sellers of health data through its proprietary Human Data Marketplace.